News
AMT-130 is administered through magnetic resonance imaging-guided, convection-enhanced stereotactic neurosurgical delivery into the striatum.
Pharmaceutical Technology on MSN3d
FDA grants breakthrough status to uniQure’s Huntington’s disease therapyThe US Food and Drug Administration (FDA) has awarded breakthrough therapy designation to uniQure's AMT-130 for treating ...
Qure's long-term success hinges on overcoming regulatory and logistical challenges. See why I rate QURE stock a hold.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback